SI-BONE(SIBN)
搜索文档
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
Newsfilter· 2024-07-16 04:09
文章核心观点 - 公司将于2024年8月5日发布2024年第二季度财务业绩报告 [1] - 公司将于2024年8月5日下午1:30(太平洋时间)/4:30(东部时间)举行财报电话会议 [1] - 公司是一家专注于解决骶盆腔肌肉骨骼疾病的医疗器械公司 [3] - 公司自2009年开创最小创伤性骶髂关节融合手术以来,已支持超过3,700名外科医生进行了超过10万例骶盆腔手术 [3] - 公司的技术得到了大量临床证据支持,包括4项随机对照试验和130多篇同行评审论文 [3] - 公司已将最小创伤性骶髂关节融合技术应用于成人畸形、脊髂固定和骨盆创伤等相邻市场 [3] 财务业绩 - 公司将于2024年8月5日发布2024年第二季度财务业绩报告 [1] - 公司将于2024年8月5日下午1:30(太平洋时间)/4:30(东部时间)举行财报电话会议 [1] 公司概况 - 公司是一家专注于解决骶盆腔肌肉骨骼疾病的医疗器械公司 [3] - 公司自2009年开创最小创伤性骶髂关节融合手术以来,已支持超过3,700名外科医生进行了超过10万例骶盆腔手术 [3] - 公司的技术得到了大量临床证据支持,包括4项随机对照试验和130多篇同行评审论文 [3] - 公司已将最小创伤性骶髂关节融合技术应用于成人畸形、脊髂固定和骨盆创伤等相邻市场 [3] 产品信息 - 公司的主要产品包括iFuse Bedrock Granite、iFuse-TORQ、SI-BONE和iFuse INTRA [4]
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
GlobeNewswire News Room· 2024-07-16 04:09
SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at t ...
SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
Newsfilter· 2024-06-06 04:09
文章核心观点 - 公司将参加即将到来的2024年Truist证券医疗技术会议 [1][2] - 公司将在会议上举办一场线上交流会 [2][3] - 公司是一家专注于解决骶盆腔肌肉骨骼疾病的医疗器械公司 [4] - 公司自2009年开始推广最小创伤性骶髂关节融合手术,已支持超过3,700名外科医生进行了超过10万例相关手术 [4] - 公司的技术得到了大量临床证据支持,包括4项随机对照试验和130多篇同行评议文章 [4] - 公司将最小创伤性骶髂关节融合技术拓展到成人畸形、脊髂固定和骨盆创伤等相邻市场 [4] 公司概况 - 公司名称为SI-BONE公司,总部位于加利福尼亚州圣克拉拉 [1] - 公司股票代码为SIBN,在纳斯达克上市 [1][4] - 公司拥有多项注册商标,包括iFuse Bedrock Granite、iFuse-TORQ、SI-BONE和iFuse INTRA [6] 投资者联系方式 - 投资者可通过电子邮箱investors@si-bone.com联系公司 [7]
SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
GlobeNewswire News Room· 2024-06-06 04:09
SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at t ...
SI-BONE(SIBN) - 2024 Q1 - Quarterly Report
2024-05-08 04:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38701 SI-BONE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2216351 (State or ...
SI-BONE(SIBN) - 2024 Q1 - Earnings Call Transcript
2024-05-07 08:47
SI-BONE, Inc. (NASDAQ:SIBN) Q1 2024 Results Conference Call May 6, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Drew Ranieri - Morgan Stanley Dave Turkaly - Citizen JMP Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Sam Brodovsky - Truist Securities Ross Osborn - ...
SI-BONE(SIBN) - 2024 Q1 - Quarterly Results
2024-05-07 04:10
Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the First Quarter 2024 Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% SANTA CLARA, Calif. May 6, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) • Worldwide reve ...
SI-BONE(SIBN) - 2023 Q4 - Annual Report
2024-02-28 05:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its Charter) Delaware 26-2216351 (State or other jurisdiction (I.R.S. E ...
SI-BONE(SIBN) - 2023 Q4 - Earnings Call Transcript
2024-02-27 12:30
SI-BONE, Inc. (NASDAQ:SIBN) Q4 2023 Earnings Call Transcript February 26, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Sam Brodovsky - Truist Securities Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Fourth Quarter 2023 Earnings Conference Call. At t ...
SI-BONE(SIBN) - 2023 Q3 - Quarterly Report
2023-11-08 05:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38701 SI-BONE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2216351 (State ...